Latest Breaking News On - Steroidal anti inflammatory agents - Page 6 : comparemela.com

Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with. | May 1, 2023

United statesJula inrigNaomi eichenbaumNivi nehraDeric dubeCorporate communicationsTravere therapeutics incEuropean unionExchange commission onCompany annual report on formEuropean medicines agencyTravere therapeuticsDual endothelin angiotensin receptor antagonistNew drug applicationConditional marketing authorizationEfficacy endpoints

Travere Therapeutics Announces Topline Results from

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended.

United statesDeric dubeJula inrigNivi nehraNaomi eichenbaumCorporate communicationsEuropean unionTravere therapeutics incExchange commission onCompany annual report on formEuropean medicines agencyTravere therapeuticsDual endothelin angiotensin receptor antagonistNew drug applicationConditional marketing authorizationEfficacy endpoints

Travere Therapeutics (TVTX) Reports Topline Results from Phase 3 DUPLEX Study of Sparsentan

Travere Therapeutics (TVTX) Reports Topline Results from Phase 3 DUPLEX Study of Sparsentan
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNaomi eichenbaumDeric dubeJula inrigNivi nehraTravere therapeutics incEuropean medicines agencyEuropean unionExchange commission onCorporate communicationsCompany annual report on formWall streetDual endothelin angiotensin receptor antagonistNew drug applicationConditional marketing authorizationEfficacy endpoints

Travere Therapeutics Announces Interim Analysis from the

FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control.

United statesKrung thep mahanakhonNaomi eichenbaumNivi nehraBrad rovinExchange commissionTravere therapeutics incWorld congressCorporate communicationsDivision for nephrologyOhio state university centerClinical research managementEuropean unionCompany annual report on formMedical directorAbout iga

Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

SAN DIEGO, April 01, 2023 Travere Therapeutics, Inc. today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, Phase 3 PROTECT. | April 1, 2023

Krung thep mahanakhonUnited statesNaomi eichenbaumNivi nehraBrad rovinDivision for nephrologyCompany annual report on formExchange commissionEuropean unionGlobenewswire incOhio state university centerWorld congressTravere therapeutics incClinical research managementCorporate communicationsMedical director